{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T11:16:37Z","timestamp":1750072597444},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to evaluate the factors that affect the local control (LC) of bone metastases from radioresistant carcinomas (renal cell carcinoma, hepatocellular carcinoma [HCC], and colorectal carcinoma [CRC]) treated with palliative external-beam radiotherapy (EBRT).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and materials<\/jats:title>\n                <jats:p>Between January 2010 and December 2020, 211 bone metastases in 134 patients were treated with EBRT in two hospitals (a cancer center and university hospital). Based on follow-up CT, these cases were reviewed retrospectively to evaluate LC at the EBRT site.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The median EBRT dose (BED10) was 39.0\u00a0Gy (range, 14.4\u201366.3\u00a0Gy). The median follow-up time of the imaging studies was 6\u00a0months (range, 1\u2013107\u00a0months). The 0.5-year overall survival and LC rates of the EBRT sites were 73% and 73%, respectively. Multivariate analysis revealed that the primary sites (HCC\/CRC), low EBRT dose (BED10) (\u2264\u200939.0\u00a0Gy), and non-administration of post-EBRT bone modifying agents (BMAs) and\/or antineoplastic agents (ATs) were statistically significant factors that negatively affected the LC of EBRT sites. In the absence of BMAs or ATs, the EBRT dose (BED10) escalation from 39.0\u00a0Gy improved the LC of EBRT sites. Based on ATs administration, the LC of EBRT sites was significantly affected by tyrosine kinase inhibitors and\/or immune checkpoint inhibitors.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Dose escalation improves LC in bone metastases from radioresistant carcinomas. Higher EBRT doses are needed to treat patients for whom few effective systemic therapies remain available.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12672-023-00651-0","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:01:41Z","timestamp":1684753301000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Factors affecting local control of bone metastases from radioresistant tumors treated with palliative external beam radiotherapy"],"prefix":"10.1007","volume":"14","author":[{"given":"Kenji","family":"Makita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromitsu","family":"Kanzaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kei","family":"Nagasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Tsuruoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Uwatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruhito","family":"Kido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"Suppl 1","key":"651_CR1","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/8756-3282(91)90059-r","volume":"12","author":"M Tubiana-Hulin","year":"1991","unstructured":"Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone. 1991;12(Suppl 1):S9-10. https:\/\/doi.org\/10.1016\/8756-3282(91)90059-r.","journal-title":"Bone"},{"key":"651_CR2","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1093\/annonc\/mdr362","volume":"23","author":"M Bianchi","year":"2012","unstructured":"Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, Briganti A, et al. Distribution of metastatic sites in renal cell carcinoma: a population\u2014based analysis. Ann Oncol. 2012;23:973\u201380. https:\/\/doi.org\/10.1093\/annonc\/mdr362.","journal-title":"Ann Oncol"},{"key":"651_CR3","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1002\/1097-0142(19850501)55:9<1991::aid-cncr2820550927>3.0.co;2-f","volume":"55","author":"N Okazaki","year":"1985","unstructured":"Okazaki N, Yoshino M, Yoshida T, Hirohashi S, Kishi K, Shimosato Y. Bone metastasis in hepatocellular carcinoma. Cancer. 1985;55:1991\u20134. https:\/\/doi.org\/10.1002\/1097-0142(19850501)55:9%3c1991::aid-cncr2820550927%3e3.0.co;2-f.","journal-title":"Cancer"},{"key":"651_CR4","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1093\/annonc\/mdr572","volume":"23","author":"D Santini","year":"2012","unstructured":"Santini D, Tampellini M, Vincenzi B, Ibrahim T, Ortega C, Virzi V, et al. Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Ann Oncol. 2012;23:2072\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdr572.","journal-title":"Ann Oncol"},{"key":"651_CR5","first-page":"2394","volume":"9","author":"A Ibrahim","year":"2003","unstructured":"Ibrahim A, Scher N, Williams G, Sridhara R, Li N, Chen G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9:2394\u20139.","journal-title":"Clin Cancer Res"},{"key":"651_CR6","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.radonc.2022.05.024","volume":"173","author":"J van der Velden","year":"2022","unstructured":"van der Velden J, Willmann J, Spa\u0142ek M, Oldenburger E, Brown S, Kazmierska J, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. Radiother Oncol. 2022;173:197\u2013206. https:\/\/doi.org\/10.1016\/j.radonc.2022.05.024.","journal-title":"Radiother Oncol"},{"key":"651_CR7","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.radonc.2022.06.002","volume":"173","author":"E Oldenburger","year":"2022","unstructured":"Oldenburger E, Brown S, Willmann J, van der Velden JM, Spa\u0142ek M, van der Linden YM, et al. ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiother Oncol. 2022;173:240\u201353. https:\/\/doi.org\/10.1016\/j.radonc.2022.06.002.","journal-title":"Radiother Oncol"},{"key":"651_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.prro.2016.08.001","volume":"7","author":"S Lutz","year":"2017","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE, et al. Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline. Pract Radiat Oncol. 2017;7:4\u201312. https:\/\/doi.org\/10.1016\/j.prro.2016.08.001.","journal-title":"Pract Radiat Oncol"},{"key":"651_CR9","doi-asserted-by":"publisher","first-page":"15182","DOI":"10.18632\/oncotarget.14858","volume":"8","author":"IH Jung","year":"2017","unstructured":"Jung IH, Yoon SM, Kwak J, Park JH, Song SY, Lee SW, et al. High-dose radiotherapy is associated with better local control of bone metastasis from hepatocellular carcinoma. Oncotarget. 2017;8:15182\u201392. https:\/\/doi.org\/10.18632\/oncotarget.14858.","journal-title":"Oncotarget"},{"key":"651_CR10","doi-asserted-by":"publisher","first-page":"6384253","DOI":"10.1155\/2018\/6384253","volume":"2018","author":"RG Ganju","year":"2018","unstructured":"Ganju RG, TenNapel M, Mahan N, Zahra A, Shen X. The efficacy of conventionally fractionated radiation in the management of osseous metastases from metastatic renal cell carcinoma. J Oncol. 2018;2018:6384253. https:\/\/doi.org\/10.1155\/2018\/6384253.","journal-title":"J Oncol"},{"key":"651_CR11","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.prro.2020.03.009","volume":"10","author":"RE Wegner","year":"2020","unstructured":"Wegner RE, Matani H, Colonias A, Price F, Furhrer R, Abel S. Trends in radiation fractionation for bone metastases: a contemporary nationwide analysis. Pract Radiat Oncol. 2020;10:402\u20138. https:\/\/doi.org\/10.1016\/j.prro.2020.03.009.","journal-title":"Pract Radiat Oncol"},{"key":"651_CR12","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318. https:\/\/doi.org\/10.1056\/NEJMoa2017699.","journal-title":"N Engl J Med"},{"key":"651_CR13","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905. https:\/\/doi.org\/10.1056\/NEJMoa1915745.","journal-title":"N Engl J Med"},{"key":"651_CR14","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/jjco\/hyq146","volume":"40","author":"Y Tomita","year":"2010","unstructured":"Tomita Y, Shinohara N, Yuasa T, Fujimoto H, Niwakawa M, Mugiya S, et al. Overall survival and updated results from a phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2010;40:1166\u201372. https:\/\/doi.org\/10.1093\/jjco\/hyq146.","journal-title":"Jpn J Clin Oncol"},{"key":"651_CR15","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s00066-010-2110-9","volume":"186","author":"K Freundt","year":"2010","unstructured":"Freundt K, Meyners T, Bajrovic A, Basic H, Karstens JH, Adamietz IA, et al. Radiotherapy for oligometastatic disease in patients with spinal cord compression (MSCC) from relatively radioresistant tumors. Strahlenther Onkol. 2010;186:218\u201323. https:\/\/doi.org\/10.1007\/s00066-010-2110-9.","journal-title":"Strahlenther Onkol"},{"key":"651_CR16","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.ijrobp.2010.04.026","volume":"80","author":"D Rades","year":"2011","unstructured":"Rades D, Freundt K, Meyners T, Bajrovic A, Basic H, Karstens JH, et al. Dose escalation for metastatic spinal cord compression in patients with relatively radioresistant tumors. Int J Radiat Oncol Biol Phys. 2011;80:1492\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2010.04.026.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"651_CR17","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13014-021-01940-0","volume":"16","author":"K Makita","year":"2021","unstructured":"Makita K, Hamamoto Y, Kanzaki H, Kataoka M, Yamamoto S, Nagasaki K, et al. Local control of bone metastases treated with external beam radiotherapy in recent years: a multicenter retrospective study. Radiat Oncol. 2021;16:225. https:\/\/doi.org\/10.1186\/s13014-021-01940-0.","journal-title":"Radiat Oncol"},{"issue":"Suppl","key":"651_CR18","doi-asserted-by":"publisher","first-page":"S78","DOI":"10.1097\/BRS.0b013e3181b8b6f5","volume":"34","author":"PC Gerszten","year":"2009","unstructured":"Gerszten PC, Mendel E, Yamada Y. Radiotherapy and radiosurgery for metastatic spine disease: what are the options, indications, and outcomes? Spine. 2009;34(Suppl):S78-92. https:\/\/doi.org\/10.1097\/BRS.0b013e3181b8b6f5.","journal-title":"Spine"},{"key":"651_CR19","doi-asserted-by":"publisher","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, \u0160eruga B, Vera-Badillo FE, Aneja P, Oca\u00f1a A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124.","journal-title":"J Natl Cancer Inst"},{"key":"651_CR20","doi-asserted-by":"publisher","first-page":"e101119","DOI":"10.1371\/journal.pone.0101119","volume":"9","author":"Xin Zhou","year":"2014","unstructured":"Zhou Xin, Yiping Du, Huang Zebo, Jun Xu, Qiu Tianzhu, Wang Jian, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLOS ONE. 2014;9:e101119. https:\/\/doi.org\/10.1371\/journal.pone.0101119.","journal-title":"PLOS ONE"},{"key":"651_CR21","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3892\/mco.2022.2585","volume":"17","author":"K Makita","year":"2022","unstructured":"Makita K, Hamamoto Y, Kanzaki H, Kataoka M, Yamamoto S, Nagasaki K, et al. Local control after palliative external beam radiotherapy for bone metastases in patients with favorable prognosis. Mol Clin Oncol. 2022;17:152. https:\/\/doi.org\/10.3892\/mco.2022.2585.","journal-title":"Mol Clin Oncol"},{"key":"651_CR22","doi-asserted-by":"publisher","first-page":"923","DOI":"10.4254\/wjh.v6.i12.923","volume":"6","author":"S Hayashi","year":"2014","unstructured":"Hayashi S, Tanaka H, Hoshi H. Palliative external-beam radiotherapy for bone metastases from hepatocellular carcinoma. World J Hepatol. 2014;6:923\u20139. https:\/\/doi.org\/10.4254\/wjh.v6.i12.923.","journal-title":"World J Hepatol"},{"key":"651_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijrobp.2022.05.043","volume":"114","author":"KL Zeng","year":"2022","unstructured":"Zeng KL, Myrehaug S, Soliman H, Husain ZA, Tseng CL, Detsky J, et al. Mature local control and reirradiation rates comparing spine stereotactic body radiation therapy with conventional palliative external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2022;114:293\u2013300. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.05.043.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"651_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ijrobp.2021.06.025","volume":"112","author":"NJ Mathis","year":"2022","unstructured":"Mathis NJ, Doyle CJ, Rosen DB, Wijetunga NA, Vaynrub M, Bartelstein M, et al. Personalized treatment selection leads to low rates of local salvage therapy for bone metastases. Int J Radiat Oncol Biol Phys. 2022;112:99\u2013105. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.06.025.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"651_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3857\/roj.2015.33.3.217","volume":"33","author":"E Lee","year":"2015","unstructured":"Lee E, Kim TG, Park HC, Yu JI, Lim DH, Nam H, et al. Clinical outcomes of stereotactic body radiotherapy for spinal metastases from hepatocellular carcinoma. Radiat Oncol J. 2015;33:217\u201325. https:\/\/doi.org\/10.3857\/roj.2015.33.3.217.","journal-title":"Radiat Oncol J"},{"key":"651_CR26","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1016\/j.wneu.2017.10.011","volume":"109","author":"BW Smith","year":"2018","unstructured":"Smith BW, Joseph JR, Saadeh YS, La Marca F, Szerlip NJ, Schermerhorn TC, et al. Radiosurgery for treatment of renal cell metastases to spine: a systematic review of the literature. World Neurosurg. 2018;109:e502\u20139. https:\/\/doi.org\/10.1016\/j.wneu.2017.10.011.","journal-title":"World Neurosurg"},{"key":"651_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.semradonc.2021.02.002","volume":"31","author":"S All","year":"2021","unstructured":"All S, Garant A, Hannan R. Stereotactic ablative radiation (SAbR) for oligometastatic RCC. Semin Radiat Oncol. 2021;31:227\u201334. https:\/\/doi.org\/10.1016\/j.semradonc.2021.02.002.","journal-title":"Semin Radiat Oncol"},{"key":"651_CR28","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1093\/jjco\/hyaa128","volume":"50","author":"K Ito","year":"2020","unstructured":"Ito K, Yamaguchi T, Ogawa H, Nakajima Y, Karasawa K. Stereotactic body radiotherapy for bone metastases in patients with colorectal cancer. Jpn J Clin Oncol. 2020;50:1442\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyaa128.","journal-title":"Jpn J Clin Oncol"},{"key":"651_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.amsu.2018.01.002","volume":"27","author":"M Umer","year":"2018","unstructured":"Umer M, Mohib Y, Atif M, Nazim M. Skeletal metastasis in renal cell carcinoma: a review. Ann Med Surg (Lond). 2018;27:9\u201316. https:\/\/doi.org\/10.1016\/j.amsu.2018.01.002.","journal-title":"Ann Med Surg (Lond)"},{"key":"651_CR30","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00066-012-0158-4","volume":"188","author":"D Rades","year":"2012","unstructured":"Rades D, Hakim SG, Bajrovic A, Karstens JH, Veninga T, Rudat V, et al. Impact of zoledronic acid on control of metastatic spinal cord compression. Strahlenther Onkol. 2012;188:910\u20136. https:\/\/doi.org\/10.1007\/s00066-012-0158-4.","journal-title":"Strahlenther Onkol"},{"key":"651_CR31","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.urolonc.2010.02.006","volume":"30","author":"M Staehler","year":"2012","unstructured":"Staehler M, Haseke N, Stadler T, Nuhn P, Roosen A, Stief CG, et al. Feasibility and effects of high-dose hypofractionated radiation therapy and simultaneous multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer. Urol Oncol. 2012;30:290\u20133. https:\/\/doi.org\/10.1016\/j.urolonc.2010.02.006.","journal-title":"Urol Oncol"},{"key":"651_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s10456-015-9476-3","volume":"18","author":"EA Kleibeuker","year":"2015","unstructured":"Kleibeuker EA, Ten Hooven MA, Verheul HM, Slotman BJ, Thijssen VL. Combining radiotherapy with sunitinib: lessons (to be) learned. Angiogenesis. 2015;18:385\u201395. https:\/\/doi.org\/10.1007\/s10456-015-9476-3.","journal-title":"Angiogenesis"},{"key":"651_CR33","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/jrr\/rraa020","volume":"61","author":"H Tanaka","year":"2020","unstructured":"Tanaka H, Makita C, Manabe Y, Kajima M, Matsuyama K, Matsuo M. Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer. J Radiat Res. 2020;61:494\u20138. https:\/\/doi.org\/10.1093\/jrr\/rraa020.","journal-title":"J Radiat Res"},{"key":"651_CR34","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00432-009-0664-7","volume":"136","author":"J Zo\u0142nierek","year":"2010","unstructured":"Zo\u0142nierek J, Nurzy\u0144ski P, Langiewicz P, Oborska S, Wa\u015bko-Grabowska A, Kuszatal E, et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol. 2010;136:371\u20138. https:\/\/doi.org\/10.1007\/s00432-009-0664-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"651_CR35","doi-asserted-by":"publisher","first-page":"871675","DOI":"10.3389\/fonc.2022.871675","volume":"12","author":"Y Asano","year":"2022","unstructured":"Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, et al. The therapeutic effect and clinical outcome of immune checkpoint inhibitors on bone metastasis in advanced non-small-cell lung cancer. Front Oncol. 2022;12:871675. https:\/\/doi.org\/10.3389\/fonc.2022.871675.","journal-title":"Front Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00651-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-023-00651-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-023-00651-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T11:56:39Z","timestamp":1684756599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-023-00651-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["651"],"URL":"https:\/\/doi.org\/10.1007\/s12672-023-00651-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,22]]},"assertion":[{"value":"31 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The need for patient consent was waived by the institutional ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients treated at Shikoku Cancer Center and Ehime University Hospital consented to an opt-out method for the use of their data for research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}